Methods Patients with advanced or metastatic pancreatic adenocarcinoma expressing GCC (H-score10) received TAK-264 1.8mg/kg on day 1 of a 21-day cycle as a 30-min intravenous infusion for up to 1year or until disease progression or unacceptable toxicity. The primary objective was overall ...
Bang YJ, Takano T, Lin CC, Fasanmade A, Yang H, Danaee H, Asato T, Kalebic T, Wang H, Doi T (2018) TAK-264 (MLN0264) in previously treated Asian patients with advanced gastrointestinal carcinoma expressing guanylyl cyclase C: results from an open-label, non-randomized phase 1 study...